Krabbe Disease

Overview


Plain-Language Overview

Krabbe Disease is a rare inherited disorder that affects the nervous system. It occurs when the body lacks an important enzyme called galactocerebrosidase, which helps break down certain fats in the brain. Without this enzyme, harmful substances build up and damage the protective covering of nerve cells, called the myelin sheath. This damage leads to problems with muscle control, movement, and development. Symptoms often begin in infancy and can include irritability, feeding difficulties, and delayed growth.

Clinical Definition

Krabbe Disease, also known as globoid cell leukodystrophy, is an autosomal recessive lysosomal storage disorder caused by mutations in the GALC gene leading to deficiency of the enzyme galactocerebrosidase. This enzyme deficiency results in accumulation of psychosine, a cytotoxic metabolite, causing widespread demyelination in the central and peripheral nervous systems. The disease typically presents in infancy with progressive neurodegeneration characterized by irritability, spasticity, developmental delay, and peripheral neuropathy. Histopathologically, it is marked by the presence of multinucleated globoid cells and loss of myelin. Diagnosis is confirmed by reduced GALC enzyme activity and genetic testing. Late-onset forms exist but are less common. The disease leads to severe neurological impairment and is usually fatal within the first two years of life without treatment. Current therapeutic options are limited, with hematopoietic stem cell transplantation showing some benefit if performed early.

Inciting Event

  • There is no specific inciting event; the disease results from inherited enzyme deficiency.

Latency Period

  • none

Diagnostic Delay

  • Early symptoms can be nonspecific, leading to misdiagnosis as other neurological disorders.
  • Lack of awareness and rarity of the disease contribute to delayed enzyme testing and diagnosis.

Clinical Presentation


Signs & Symptoms

  • Progressive psychomotor regression beginning in infancy.
  • Irritability and feeding difficulties.
  • Seizures in advanced stages.
  • Spasticity and hyperreflexia.
  • Peripheral neuropathy causing muscle weakness and hypotonia.

History of Present Illness

  • Infants typically present with irritability, feeding difficulties, and progressive stiffness or spasticity.
  • Developmental regression and loss of motor milestones are common.
  • Seizures and vision loss may develop as the disease progresses.

Past Medical History

  • No specific past medical history is typically present before symptom onset in infants.

Family History

  • A positive family history of Krabbe disease or unexplained infant deaths suggests autosomal recessive inheritance.
  • Consanguinity may increase risk due to higher chance of inheriting two defective alleles.

Physical Exam Findings

  • Presence of hypertonia and increased deep tendon reflexes due to central nervous system involvement.
  • Marked developmental delay and regression in motor milestones.
  • Optic atrophy leading to visual impairment.
  • Peripheral neuropathy signs such as muscle weakness and decreased reflexes in later stages.

Diagnostic Workup


Diagnostic Criteria

Diagnosis of Krabbe Disease is based on clinical presentation of progressive neurological symptoms in infancy, reduced galactocerebrosidase enzyme activity in leukocytes or fibroblasts, and identification of pathogenic mutations in the GALC gene. Neuroimaging typically shows diffuse white matter abnormalities consistent with demyelination. Histological examination may reveal characteristic globoid cells. Newborn screening programs may detect enzyme deficiency before symptom onset.

Pathophysiology


Key Mechanisms

  • Krabbe disease is caused by a deficiency of the lysosomal enzyme galactocerebrosidase (GALC), leading to accumulation of toxic metabolites like psychosine.
  • The buildup of psychosine results in widespread demyelination of the central and peripheral nervous systems.
  • Loss of oligodendrocytes and Schwann cells due to toxic metabolite accumulation causes progressive neurological decline.
InvolvementDetails
Organs Brain is the main organ affected, showing progressive demyelination and neurological decline.
Peripheral nervous system involvement leads to motor and sensory deficits.
Tissues White matter of the central nervous system is primarily affected due to demyelination.
Peripheral nerves also undergo demyelination leading to peripheral neuropathy.
Cells Oligodendrocytes are the primary cells affected in Krabbe disease due to accumulation of toxic metabolites causing demyelination.
Macrophages accumulate as globoid cells in the nervous system and contribute to neuroinflammation.
Chemical Mediators Psychosine accumulates due to deficient galactocerebrosidase and is toxic to myelin-producing cells.
Proinflammatory cytokines released by activated macrophages contribute to neurodegeneration.

Treatment


Pharmacological Treatments

  • Hematopoietic stem cell transplantation (HSCT)

    • Mechanism: Provides donor-derived cells that can produce functional galactocerebrosidase enzyme to reduce substrate accumulation
    • Side effects: Graft-versus-host disease, infection, transplant-related mortality

Non-pharmacological Treatments

  • Supportive care including physical therapy to maintain mobility and prevent contractures.
  • Nutritional support to manage feeding difficulties and maintain adequate growth.
  • Respiratory support to manage recurrent infections and respiratory insufficiency.

Prevention


Pharmacological Prevention

  • None currently available; no approved drug-based prevention.

Non-pharmacological Prevention

  • Newborn screening for early detection in at-risk populations.
  • Hematopoietic stem cell transplantation (HSCT) in presymptomatic patients may slow disease progression.

Outcome & Complications


Complications

  • Respiratory failure due to bulbar dysfunction and aspiration pneumonia.
  • Seizure disorders secondary to progressive CNS demyelination.
  • Nutritional deficiencies from feeding difficulties.
Short-term SequelaeLong-term Sequelae
  • Rapid neurological deterioration with loss of motor skills.
  • Increased risk of infections due to impaired swallowing and respiratory compromise.
  • Severe intellectual disability and permanent motor impairment.
  • Chronic respiratory insufficiency requiring supportive care.
  • Early death typically within the first few years of life in infantile form.

Differential Diagnoses


Krabbe Disease versus Adrenoleukodystrophy

Krabbe DiseaseAdrenoleukodystrophy
Autosomal recessive inheritance without adrenal insufficiencyX-linked inheritance with adrenal insufficiency and progressive neurologic decline
Normal VLCFA levels in plasmaVery long chain fatty acids (VLCFA) accumulation in plasma
MRI shows diffuse cerebral white matter involvement including corticospinal tractsMRI shows occipital white matter demyelination

Krabbe Disease versus Canavan Disease

Krabbe DiseaseCanavan Disease
Galactocerebrosidase deficiency with no NAA accumulationAspartoacylase deficiency causing accumulation of N-acetylaspartic acid (NAA)
Normal head circumference or microcephaly in early infancyMacrocephaly and severe developmental delay in infancy
MRI shows globoid cells and demyelination without spongiform changesMRI shows diffuse symmetric white matter spongiform changes

Krabbe Disease versus Metachromatic Leukodystrophy

Krabbe DiseaseMetachromatic Leukodystrophy
Galactocerebrosidase deficiency causing accumulation of psychosineArylsulfatase A deficiency leading to accumulation of sulfatides
Rapid infantile onset with irritability, spasticity, and peripheral neuropathyDemyelination predominantly affecting the central and peripheral nervous system with ataxia and dementia
Elevated psychosine levels in blood and decreased galactocerebrosidase activityTandem mass spectrometry shows elevated sulfatides in urine

Medical Disclaimer: The content on this site is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you think you may be experiencing a medical emergency, call 911 or your local emergency number immediately. Always consult a licensed healthcare professional with questions about a medical condition.

Artificial Intelligence Use: Portions of this site’s content were generated or assisted by AI and reviewed by Erik Romano, MD; however, errors or omissions may occur.

USMLE® is a registered trademark of the Federation of State Medical Boards (FSMB) and the National Board of Medical Examiners (NBME). Doctogenic and Roscoe & Romano are not affiliated with, sponsored by, or endorsed by the USMLE, FSMB, or NBME. Neither FSMB nor NBME has reviewed or approved this content. “USMLE Step 1” and “USMLE Step 2 CK” are used only to identify the relevant examinations.